| Factor Information | |
|---|---|
| Data ID | 25 |
| Factor | 9 and 13-hydroxyoctadecadienoic acid level (9:13-HODE) |
| Description | 9-HODE and 13-HODE levels (normalized to linoleic acid [LA]) increased during cardiopulmonary bypass and the ratio of 9:13-HODE decreased from start of cardiopulmonary bypass (StartCPB) to end of cardiopulmonary bypass (EndCPB) |
| Biomarker | NA |
| Classification | E2 (physiological factor - biochemical index) |
| Association | |
|---|---|
| Application | prognosis |
| Objective | To access plasma HODE and its association with CPB Duration, Milrinone Use, VIS. |
| p Value | <0.01 |
| Conclusion | 9-HODE and 13-HODE levels (normalized to linoleic acid [LA]) increased during cardiopulmonary bypass and the ratio of 9:13-HODE decreased from start of cardiopulmonary bypass (StartCPB) to end of cardiopulmonary bypass (EndCPB). |
| Risk Factor | unknown |
| CHD Type | |
|---|---|
| ID | 148 |
| CHD Type | NA |
| CHD Subtype | NA |
| Reference | |
|---|---|
| PMID | 31305328 |
| Year | 2019 |
| Title | Bioactive Oxylipins in Infants and Children With Congenital Heart Disease Undergoing Pediatric Cardiopulmonary Bypass. |
| Sample | ||
|---|---|---|
| Population | Infants and Children | |
| Source | plasma | |
| Region | Pittsburgh, USA | |
| Method | Plasma was collected at the start and end of cardiopulmonary bypass in 34 patients. 9-hydroxyoctadecadienoic acid, 13-hydroxyoctadecadienoic acid, plasma hemoglobin, and WBC increased. | |
| Race | North America | |
| Disease History | N/A | |
| Treatment History | Pediatric Cardiopulmonary Bypass, cardiac surgery | |
| Group | start CPB(Treatment) | end CPB(Control) |
| Number | 34 | 34 |
| Age | 2.5 (0.6–12.0) years | 2.5 (0.6–12.0) years |
| Gender (Male: Female) | 18:16 | 18:16 |
| Marker Level | N/A | N/A |
